Nanki Toshihiro

Articles:  1-1 of 1

  • Head-to-head comparison of the safety of tocilizumab and tumor necrosis factor inhibitors in rheumatoid arthritis patients (RA) in clinical practice: Results from the registry of Japanese RA patients on biologics for long-term safety (REAL) registry

    Sakai Ryoko , Cho Soo Kyung , Nanki Toshihiro , Watanabe Kaori , Yamazaki Hayato , Tanaka Michi , Koike Ryuji , Tanaka Yoshiya , Saito Kazuyoshi , Hirata Shintaro , Amano Koichi , Nagasawa Hayato , Sumida Takayuki , Hayashi Taichi , Sugihara Takahiko , Dobashi Hiroaki , Yasuda Shinsuke , Sawada Tetsuji , Ezawa Kazuhiko , Ueda Atsuhisa , Fujii Takao , Migita Kiyoshi , Miyasaka Nobuyuki , Harigai Masayoshi , Atsumi Tatsuya , Ishigatsubo Yoshiaki , Ihata Atsushi , Mimori Tsuneyo , Takasaki Yoshinari , Tamura Naoto , Hashiramoto Akira , Shiozawa Syunichi , Kameda Hideto , Kaneko Yuko , Takeuchi Tsutomu , Ochi Sae , Miura Yasushi , Nonomura Yoshinori , Nakajima Atsuo , Michishita Kazuya , Yamamoto Kazuhiko , Ueki Yukitaka , Nagasaka Kenji , Okada Akitomo , Kawakami Atsushi , Tohma Shigeto , Nakajima Ayako , Yamanaka Hisashi

    Introduction: The objective of this study was to directly compare the safety of tocilizumab (TCZ) and TNF inhibitors (TNFIs) in rheumatoid arthritis (RA) patients in clinical practice. Methods: This p …

    Arthritis Research and Therapy (17), 2015-03-23

    IR 

Page Top